Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria.

Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2

(2021) Prince Singh et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hepatic Lactate Dehydrogenase A is an RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria

(2021) Gema Ariceta et al.   Kidney International Reports

A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3

(2021) Cristina Martin-Higueras et al.   KIDNEY INTERNATIONAL

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

(2021) Sander F. Garrelfs et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endpoints for Clinical Trials in Primary Hyperoxaluria

(2020) Dawn S. Milliner et al.   Clinical Journal of the American Society of Nephrology

Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity

(2019) Kyle D. Wood et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up

(2019) Sander F. Garrelfs et al.   KIDNEY INTERNATIONAL

Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria

(2018) Chengjung Lai et al.   MOLECULAR THERAPY

Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure

(2015) F. Zhao et al.   Clinical Journal of the American Society of Nephrology

Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria

(2015) K. Hopp et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Renal function can be impaired in children with primary hyperoxaluria type 3

(2015) Lise Allard et al.   PEDIATRIC NEPHROLOGY

Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type

(2014) Giorgia Mandrile et al.   KIDNEY INTERNATIONAL

NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy

(2013) Felix Knauf et al.   KIDNEY INTERNATIONAL

Primary Hyperoxaluria

(2013) Pierre Cochat et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hereditary causes of kidney stones and chronic kidney disease

(2013) Vidar O. Edvardsson et al.   PEDIATRIC NEPHROLOGY

An update on primary hyperoxaluria

(2012) Bernd Hoppe   Nature Reviews Nephrology

Primary Hyperoxaluria Type III Gene HOGA1 (Formerly DHDPSL) as a Possible Risk Factor for Idiopathic Calcium Oxalate Urolithiasis

(2011) C. G. Monico et al.   Clinical Journal of the American Society of Nephrology

Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III

(2010) Ruth Belostotsky et al.   AMERICAN JOURNAL OF HUMAN GENETICS

New Equations to Estimate GFR in Children with CKD

(2009) G. J. Schwartz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome

(2009) Jérôme Harambat et al.   KIDNEY INTERNATIONAL